14892-97-8
SCR7
CAS: 14892-97-8
Molecular Formula: C18H12N4OS
14892-97-8 - Names and Identifiers
14892-97-8 - Physico-chemical Properties
| Molecular Formula | C18H12N4OS |
| Molar Mass | 332.38 |
| Density | 1.42±0.1 g/cm3(Predicted) |
| Melting Point | 209 °C |
| Solubility | DMSO (Slightly), Methanol (Slightly) |
| Appearance | powder |
| Color | faintly yellow to dark yellow |
| pKa | 4.14±0.60(Predicted) |
| Storage Condition | room temp |
14892-97-8 - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 3.009 ml | 15.043 ml | 30.086 ml |
| 5 mM | 0.602 ml | 3.009 ml | 6.017 ml |
| 10 mM | 0.301 ml | 1.504 ml | 3.009 ml |
| 5 mM | 0.06 ml | 0.301 ml | 0.602 ml |
Last Update：2024-01-02 23:10:35
14892-97-8 - Reference Information
| biological activity | SCR7 pyrazine is a DNA ligase IV inhibitor, it blocks non-homologous end joining (NHEJ) in a Ligase IV-dependent manner. SCR7 pyrazine, also an enhancer of CRISPR/Cas9, increases the efficiency of Cas9-mediated homology-directed repair (HDR). SCR7 pyrazine induces apoptosis and has anti-cancer activity. |
| Target | DNA Ligase IV CRISPR/Cas9 |
| Cell Line: | MCF7 cells |
| Concentration: | 20 μM, 40 μM, 100 μM |
| Incubation Time: | 24 hours |
| Result: | Showed an increase in levels of gH2AX foci and protein. Significantly reduced breast adenocarcinoma-induced tumor and increased lifespan. |
| Animal Model: | BALB/c mice injected with breast adenocarcinoma cells |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; on alternate days (0, 2, 4, 6, 8, and 10) |
Last Update：2024-04-09 20:52:54
Supplier List
Spot supply
Product Name: SCR7 Visit Supplier Webpage Request for quotationCAS: 14892-97-8
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: SCR7 Visit Supplier Webpage Request for quotationCAS: 14892-97-8
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History